Medicamen Biotech PE ratio, market cap and valuation
NSE: MEDICAMEQBSE: 531146Pharmaceuticals & BiotechnologySmall Cap
Last close ₹253.35down ₹11.80 (4.45%)BSE ₹253.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹265.15.
52-week range of traded prices to 23 Oct 2026
₹212.40Low, 29 Jun 2026₹447.65High, 25 Nov 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹344 Cr1,991st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.39%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 3.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day.
- 20,122
Medicamen Biotech PE ratio and valuation against its own history
Each ratio on 23 Oct 2026 beside its median over each window. The ratios are on standalone accounts to Mar 2020 and consolidated from Mar 2021. The PE ratio is the market cap over the profit of the last twelve months.
- Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
- Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.1.25today
1 year
Median 1.37Today is at or above 32% of the 232 days
3 years
Median 2.65Today is at or above 13% of the 595 days
5 years
Median 3.67Today is at or above 7% of the 1,091 days
10 years, since Nov 2018
Median 4.31Today is at or above 4% of the 1,751 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.1.70today
1 year
Median 2.16Today is at or above 21% of the 247 days
3 years
Median 3.21Today is at or above 7% of the 731 days
5 years
Median 3.86Today is at or above 4% of the 1,227 days
10 years, since Jun 2017
Median 5.06Today is at or above 3% of the 2,065 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.18.52today
1 year
Median 26.48Today is at or above 26% of the 232 days
3 years
Median 29.37Today is at or above 10% of the 595 days
5 years
Median 34.15Today is at or above 6% of the 1,091 days
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.39%today
1 year
Median 0.35%Today is at or above 70% of the 247 days
3 years
Median 0.24%Today is at or above 90% of the 744 days
5 years
Median 0.19%Today is at or above 94% of the 1,240 days
10 years
Median 0.00%Today is at or above 97% of the 2,479 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
The twelve months: Filed 14 AugThe balance sheet: Filed 27 May
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet.₹276 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹203 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet.₹48 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹34 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹19 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.1,35,62,815at 30 Sep 2026
Consolidated accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Medicamen Biotech financials ›
Medicamen Biotech valuation at each year end
On the last trading day of each March, the month the company's year ends.Medicamen Biotech dividend history
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 546 | 678 | 567 | 221 | 652 | 783 | 834 | 486 | 610 | 303 |
| Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. | No full year | 73.9 | 51.4 | No full year | 59.4 | 49.6 | 60.8 | Earlier quarters restated in the year | 82.8 | Earlier quarters restated in the year |
| Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. | No balance sheet | No balance sheet | 7.0 | 1.9 | 5.1 | 5.6 | 4.5 | 2.4 | 2.8 | 1.1 |
| Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales. | No full year | 6.5 | 4.8 | No full year | 5.7 | 6.9 | 6.7 | 2.8 | 3.4 | 1.8 |
| EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them. | No full year | No balance sheet | 33.8 | No full year | 37.4 | 35.1 | 37.2 | 21.8 | 29.4 | 23.8 |
| Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.15% | 0.26% | 0.21% | 0.45% |
| Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down. | No full year | 1.4% | 1.9% | No full year | 1.7% | 2.0% | 1.6% | Earlier quarters restated in the year | 1.2% | Earlier quarters restated in the year |
A ratio that does not exist on the day says why in its cell. The ratios are on standalone accounts to Mar 2020 and consolidated from Mar 2021.
Medicamen Biotech market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
Book value and enterprise value
From the close on 23 Oct 2026.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹357 Cr
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹203.17
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- ₹1.00
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹205 Cr
Against Pharmaceuticals
216 listed companies in Pharmaceuticals, each priced on its last trading day; Medicamen Biotech is 112th among them by market cap. Each median leaves out Medicamen Biotech itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.2Across 156 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 186 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 18.7Across 141 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.53%Across 88 other companies